Moreover, the YRS inhibitor ML901, exhibits whole-life-cycle killing activity in a mouse model of malaria (Xie et al., 2022), and the LRS inhibitor GSK656, has been used in clinical trials for systemic use against tuberculosis (Tenero et al., 2019). Here, LARS1 is linked to tuberculosis.